Fig. 1

Expression levels of EZH2 and EZH2-associated molecules in multiple sclerosis patients and controls. mRNA expression levels for EZH2, TLN1, and VAV1 were determined in PBMC from untreated multiple sclerosis patients and healthy controls by real-time PCR relative quantification, as described in the “Methods” section. Graphs showing expression levels for EZH2, TLN1, and VAV1 a–c in the initial discovery cohort and d in an independent cohort of patients and controls. Results are expressed as fold change (standard error of the mean) in gene expression in multiple sclerosis patients relative to controls and in patients in relapse relative to patients in remission. Statistics: unpaired Student’s t test. *p values < 0.05; **p values < 0.01; ***p values < 0.001. HC healthy controls, MS whole group of multiple sclerosis patients, RRMS relapsing-remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, PPMS primary progressive multiple sclerosis, Remission RRMS patients in clinical remission, Relapse RRMS patients whose blood was collected at the time of an acute exacerbation, EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit, TLN1 talin 1, VAV1 vav guanine nucleotide exchange factor 1